Skip to main content
. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98

Table 5.

Percentage utilisation of oral generic risperidone versus total risperidone (DDD basis) and percentage reduction in expenditure per defined daily dose for oral generic risperidone versus pre-patent loss prices by the end of the study period in each country

Country Utilisation of generic risperidone, % Price reduction, %
Belgium
52
59
Ireland
14
28
Scotland
98
84
Sweden 96 80